AVCT Avacta Group

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.

The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and preclinical pharmacology highlights for AVA6103, a PDC comprised of the pre|CISION® peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform.

Details for Avacta’s poster presentations are below and can be found on the :

Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage

  • Session Category: Experimental and Molecular Therapeutics
  • Session Title: Therapeutic Approach to Attack the Tumor Microenvironment
  • Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT

Abstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights

  • Session Category: Tumor Biology
  • Session Title: Targeting the Tumor Microenvironment: A Brave New World
  • Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT

Abstract Number and Title: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates

  • Session Title: First-in-Human Phase I Clinical Trials 2
  • Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CT



For further information from Avacta, please contact:

Avacta Group plc

Michael Vinegrad, Group Communications

Director
  
Peel Hunt (Nomad and Broker)

James Steel / Chris Golden







Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers



ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert


 
Investor Contact

Renee Leck

THRUST Strategic Communications









Media Contact

Carly Scaduto

Carly Scaduto Consulting
 

 

About Avacta 

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.



EN
26/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avacta Group

 PRESS RELEASE

Avacta Provides Business Update for the First Quarter of 2025 Outlinin...

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION® platform Transformation into a pure-play therapeutics company prioritizes proprietary pre|CISION® platform and extends cash runway into Q1 2026 LONDON and PHILADELPHIA, March 3...

 PRESS RELEASE

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meetin...

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL. The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Avacta: Executing steadily on therapeutics focused strategy

Avacta continues its transition into a pure-play therapeutics company to advance its pre|CISION-enabled peptide-drug conjugate platform. The expanding pipeline has the potential to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Progress has been tangible with early efficacy and safety data from the Phase Ia salivary gland cancer (SGC) dose escalation cohort of lead asset AVA6000 (FAP-Dox), and confirmation of dosing and ongoing enrolment into Phase Ib ...

 PRESS RELEASE

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare C...

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami. A live webcast of the presentation will be available in the investors section of the Company’s website at /investors. The webcas...

 PRESS RELEASE

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 ...

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch